JP6928000B2 - 化学療法の改善 - Google Patents

化学療法の改善 Download PDF

Info

Publication number
JP6928000B2
JP6928000B2 JP2018555499A JP2018555499A JP6928000B2 JP 6928000 B2 JP6928000 B2 JP 6928000B2 JP 2018555499 A JP2018555499 A JP 2018555499A JP 2018555499 A JP2018555499 A JP 2018555499A JP 6928000 B2 JP6928000 B2 JP 6928000B2
Authority
JP
Japan
Prior art keywords
composition
administered
platin
cancer
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018555499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513812A5 (enExample
JP2019513812A (ja
Inventor
ケリー グレイアム
ケリー グレイアム
Original Assignee
ノクソファーム リミティド
ノクソファーム リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノクソファーム リミティド, ノクソファーム リミティド filed Critical ノクソファーム リミティド
Publication of JP2019513812A publication Critical patent/JP2019513812A/ja
Publication of JP2019513812A5 publication Critical patent/JP2019513812A5/ja
Priority to JP2021127278A priority Critical patent/JP7193591B2/ja
Application granted granted Critical
Publication of JP6928000B2 publication Critical patent/JP6928000B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018555499A 2016-04-22 2017-04-21 化学療法の改善 Expired - Fee Related JP6928000B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021127278A JP7193591B2 (ja) 2016-04-22 2021-08-03 化学療法の改善

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326144P 2016-04-22 2016-04-22
US62/326,144 2016-04-22
PCT/AU2017/050363 WO2017181242A1 (en) 2016-04-22 2017-04-21 Chemotherapy improvements

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021127278A Division JP7193591B2 (ja) 2016-04-22 2021-08-03 化学療法の改善

Publications (3)

Publication Number Publication Date
JP2019513812A JP2019513812A (ja) 2019-05-30
JP2019513812A5 JP2019513812A5 (enExample) 2020-05-28
JP6928000B2 true JP6928000B2 (ja) 2021-09-01

Family

ID=60115481

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555499A Expired - Fee Related JP6928000B2 (ja) 2016-04-22 2017-04-21 化学療法の改善
JP2021127278A Active JP7193591B2 (ja) 2016-04-22 2021-08-03 化学療法の改善

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021127278A Active JP7193591B2 (ja) 2016-04-22 2021-08-03 化学療法の改善

Country Status (6)

Country Link
US (1) US20190117620A1 (enExample)
EP (2) EP4035667A1 (enExample)
JP (2) JP6928000B2 (enExample)
AU (2) AU2017254774B2 (enExample)
CA (1) CA3058505A1 (enExample)
WO (1) WO2017181242A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
EP3439644B1 (en) * 2016-04-06 2022-01-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CA3058500A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Targeted drug delivery
AU2017254774B2 (en) * 2016-04-22 2021-10-21 Noxopharm Limited Chemotherapy improvements
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
JP2007525485A (ja) 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
AU2017254774B2 (en) 2016-04-22 2021-10-21 Noxopharm Limited Chemotherapy improvements

Also Published As

Publication number Publication date
AU2021266308A1 (en) 2021-12-09
AU2017254774A1 (en) 2018-11-15
CA3058505A1 (en) 2017-10-26
JP7193591B2 (ja) 2022-12-20
EP3445347B1 (en) 2022-03-30
EP4035667A1 (en) 2022-08-03
AU2021266308B2 (en) 2022-12-01
AU2017254774B2 (en) 2021-10-21
WO2017181242A1 (en) 2017-10-26
EP3445347A4 (en) 2019-10-30
JP2019513812A (ja) 2019-05-30
US20190117620A1 (en) 2019-04-25
EP3445347A1 (en) 2019-02-27
JP2021169534A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7193591B2 (ja) 化学療法の改善
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
PT2127652E (pt) Agente libertador da hormona estimuladora dos folículos
EP3439644B1 (en) Isoflavonoid composition with improved pharmacokinetics
JP2021523169A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
WO2024088273A1 (zh) 一种萘酰胺化合物治疗kras突变相关疾病的用途
JP2021523189A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物およびその使用方法
TW200940062A (en) Combination comprising paclitaxel for treating ovarian cancer
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
TWI834868B (zh) 難治性癌症之預防或治療用之醫藥組合物
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
CN109475522A (zh) 改善癌症治疗
JP2011514355A (ja) 肺癌、腺癌及び他の病状のための治療方法及び組成物
TWI650141B (zh) 包含奎寧鹽懸浮液的用於抗癌治療的局部給藥用注射劑組合物
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
JP2025508548A (ja) 淡明細胞型腎細胞癌の治療
JP2025509613A (ja) がん治療のためのＭｅｔＡＰ２阻害剤を含む組み合わせ
CN117769416A (zh) Bak激活剂、药物组合物和在治疗癌症中的用途
JP2010111582A (ja) リファンピシンを成分とする肝臓癌治療剤
HK1178458A (en) Therapeutic agent for liver cancer
HK1138797A (zh) 肝癌治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210805

R150 Certificate of patent or registration of utility model

Ref document number: 6928000

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees